Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470131 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
A Phase 3 study, sponsored by AB Science.
- Terminated
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT01470131 is a Phase 3 study that was terminated before completion, run by AB Science. The registered enrollment target is 147 participants.
The verdict
NCT01470131, a Phase 3 study, was terminated before completion, sponsored by AB Science.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Masitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01470131
The ClinicalTrials.gov registry entry for NCT01470131 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AB Science, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01470131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01470131 about?
NCT01470131 is a clinical study titled "A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma". The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.
What is the current status of trial NCT01470131?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2011-05. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01470131?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Bortezomib (DRUG), Masitinib (DRUG).
Who is sponsoring clinical trial NCT01470131?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.